aspirin has been researched along with Polycythemia Vera in 133 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Polycythemia Vera: A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of aspirin in the antithrombotic strategy of patients with polycythemia vera (PV) and essential thrombocythemia (ET) is highly controversial." | 10.18 | Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. ( Landolfi, R; Patrono, C, 1996) |
| "We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily)." | 9.11 | Efficacy and safety of low-dose aspirin in polycythemia vera. ( Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004) |
| " MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromelalgia in the toes or fingers." | 7.81 | Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ( Berneman, Z; De Raeve, H; Gadisseur, A; Lam, KH; Michiels, JJ; Schroyens, W, 2015) |
| "Increased thromboxane (TX) production and modified aspirin sensitivity has been detected in vitro in platelets isolated from patients with polycythemia vera." | 7.68 | Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. ( Bizzi, B; Castellana, MA; Ciabattoni, G; Landolfi, R; Patrignani, P; Patrono, C; Pogliani, E, 1992) |
| "Recurrent mesenteric arterial thrombosis developed in a 56-year-old man with polycythemia vera (PV) despite therapy with heparin sodium, warfarin sodium, and standard doses of aspirin and dipyridamole." | 7.66 | Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin. ( Myers, TJ; Rickles, FR; Steinberg, WM, 1979) |
| "The role of aspirin in the antithrombotic strategy of patients with polycythemia vera (PV) and essential thrombocythemia (ET) is highly controversial." | 6.18 | Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. ( Landolfi, R; Patrono, C, 1996) |
| "Rates of hemorrhage were similar for aspirin in combination with warfarin or direct-acting oral anticoagulants." | 5.72 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. ( Colucci, PM; Grunwald, MR; Lessen, DS; Paranagama, D; Zwicker, JI, 2022) |
| "We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily)." | 5.11 | Efficacy and safety of low-dose aspirin in polycythemia vera. ( Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004) |
| "In the past, management of polycythemia vera (PV) was built upon a cornerstone of control over erythrocytosis, through therapeutic phlebotomy, as well as the use of low-dose aspirin." | 4.89 | Polycythemia vera: current pharmacotherapy and future directions. ( Geyer, H; Hensley, B; Mesa, R, 2013) |
| " An algorithm for the treatment of patients with erythremia is proposed along with recommendations on the use of aspirin, hydroxyurea, alpha-interpheron, and imatinib." | 4.88 | [True polycythemia: current views of pathogenesis, diagnostics and treatment]. ( Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT, 2012) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| " MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromelalgia in the toes or fingers." | 3.81 | Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ( Berneman, Z; De Raeve, H; Gadisseur, A; Lam, KH; Michiels, JJ; Schroyens, W, 2015) |
| " Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease." | 3.81 | Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. ( Barbui, T; Carobbio, A; Finazzi, G; Gisslinger, H; Pardanani, A; Passamonti, F; Pieri, L; Rambaldi, A; Randi, ML; Rodeghiero, F; Rumi, E; Tefferi, A; Thiele, J; Vannucchi, AM, 2015) |
| "This study was designed to compare the oxidative stress parameters of patients with polycythemia vera (PV) to those of healthy volunteers and to investigate the probable relationship between vascular events and parameters of oxidative status such as total oxidative status (TOS), total antioxidant status, oxidative stress index (OSI) and malondialdehyde (MDA) in PV patients." | 3.80 | The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. ( Akalin, I; Alver, A; Durmus, A; Mentese, A; Sumer, A; Topal, C; Yilmaz, M, 2014) |
| "Increased thromboxane (TX) production and modified aspirin sensitivity has been detected in vitro in platelets isolated from patients with polycythemia vera." | 3.68 | Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. ( Bizzi, B; Castellana, MA; Ciabattoni, G; Landolfi, R; Patrignani, P; Patrono, C; Pogliani, E, 1992) |
| "Recurrent mesenteric arterial thrombosis developed in a 56-year-old man with polycythemia vera (PV) despite therapy with heparin sodium, warfarin sodium, and standard doses of aspirin and dipyridamole." | 3.66 | Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin. ( Myers, TJ; Rickles, FR; Steinberg, WM, 1979) |
| " Twenty-four hours after an uncomplicated procedure she had a severe bleeding diathesis following the ingestion of a small amount of aspirin." | 3.66 | Salicylate-induced bleeding problem in ophthalmic plastic surgery. ( Paris, GL; Waltuch, GF, 1982) |
| "Pregnancy is not contraindicated in MPNs, and we recommend aspirin throughout pregnancy with consideration for prophylactic postpartum anticoagulation." | 2.72 | Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera. ( Hobbs, G; How, J, 2021) |
| "Controlled studies are needed to confirm the clinical outcome value of twice-daily vs once-daily aspirin dosing and the therapeutic role of pegylated interferons and direct oral anticoagulants." | 2.66 | Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2020) |
| "An absolute erythrocytosis is present when the red cell mass is greater than 125 % of the predicted value for sex and body mass." | 2.53 | Investigation and Management of Erythrocytosis. ( McMullin, MF, 2016) |
| "Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis." | 2.52 | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2015) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Having eliminated the common entity polycythemia vera, further direction for investigation is guided by the erythropoietin level." | 2.45 | Idiopathic erythrocytosis: a disappearing entity. ( McMullin, MF, 2009) |
| "The principal risks of essential thrombocythemia include thrombosis, major hemorrhage, and conversion to leukemia or myelofibrosis." | 2.41 | Therapeutic options for essential thrombocythemia and polycythemia vera. ( Solberg, LA, 2002) |
| "Erythromelalgia was localized in the forefoot sole and toes in 28, the fingertips in 9, the handpalm in 2." | 2.39 | Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. ( Lindemans, J; Michiels, JJ; van Genderen, PJ; van Vliet, HH, 1996) |
| "Bleeding and thrombosis are major causes of morbidity and mortality in patients with myeloproliferative disorders." | 2.37 | Bleeding and thrombosis in the myeloproliferative disorders. ( Schafer, AI, 1984) |
| "Hydroxyurea was the most frequently used drug followed by ruxolitinib, while interferons were reported for a minority of patients." | 1.72 | Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera. ( Crodel, CC; Heidel, FH; Jacobasch, L; Jentsch-Ullrich, K; Palandri, F; Reiser, M; Sauer, A; Tesch, H; Ulshöfer, T; Wunschel, R, 2022) |
| "Rates of hemorrhage were similar for aspirin in combination with warfarin or direct-acting oral anticoagulants." | 1.72 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. ( Colucci, PM; Grunwald, MR; Lessen, DS; Paranagama, D; Zwicker, JI, 2022) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation." | 1.46 | Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( Barbui, T; Tefferi, A, 2017) |
| "Mechanical valve thrombosis is a rare condition in an adequately anticoagulated patient in the absence of underlying thrombophilia." | 1.37 | Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report. ( Cherian, SV; Das, S; Gajra, A; Garcha, AS; Jasti, S; Karachiwala, H, 2011) |
| "The myeloproliferative disorders have been the "poor cousins" in the family of hematological malignancies for some time." | 1.33 | Platelets and thrombosis in myeloproliferative diseases. ( Harrison, CN, 2005) |
| "Polycythemia vera is an extremely uncommon disease in childhood and for this reason its treatment is not well established." | 1.31 | Polycythemia vera in a 12-year-old girl: a case report. ( Atabay, B; Oniz, H; Ozer, EA; Turker, M; Yaprak, I, 2002) |
| "Lawrence and the use of 32P as a treatment for polycythemia vera, to the formation of French and Italian polycythemia study groups." | 1.30 | Polycythemia vera: a retrospective and reprise. ( Berlin, NI; Wasserman, LR, 1997) |
| "Hydroxyurea was given to patients with ET with a positive history for major vascular complications or with an extreme thrombocytosis." | 1.30 | Acute coronary disease in essential thrombocythemia and polycythemia vera. ( Girolami, A; Randi, ML; Rinaldi, V; Rossi, C; Zerbinati, P, 1998) |
| "One pregnancy was electively terminated after extensive thrombosis in the splanchnic district requiring surgical entero-resection." | 1.29 | Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. ( Arrigoni, L; Muggiasca, ML; Pagliaro, P; Poggio, M; Rossi, E; Russo, U, 1996) |
| "Erythromelalgia was the presenting symptom in 26 of 40 patients with thrombocythemia in its primary form or when associated with polycythemia vera." | 1.27 | Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. ( Abels, J; Michiels, JJ; Steketee, J; van Vliet, HH; Vuzevski, VD, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (20.30) | 18.7374 |
| 1990's | 15 (11.28) | 18.2507 |
| 2000's | 36 (27.07) | 29.6817 |
| 2010's | 43 (32.33) | 24.3611 |
| 2020's | 12 (9.02) | 2.80 |
| Authors | Studies |
|---|---|
| How, J | 1 |
| Hobbs, G | 1 |
| Burattini, M | 1 |
| Falsetti, L | 1 |
| Potente, E | 1 |
| Rinaldi, C | 1 |
| Bartolini, M | 1 |
| Buratti, L | 1 |
| Silvestrini, M | 1 |
| Viticchi, G | 1 |
| Crodel, CC | 1 |
| Jentsch-Ullrich, K | 1 |
| Reiser, M | 1 |
| Jacobasch, L | 1 |
| Sauer, A | 1 |
| Tesch, H | 1 |
| Ulshöfer, T | 1 |
| Wunschel, R | 1 |
| Palandri, F | 1 |
| Heidel, FH | 1 |
| Goulart, H | 1 |
| Mascarenhas, J | 3 |
| Tremblay, D | 1 |
| Edahiro, Y | 2 |
| Nicol, C | 1 |
| Ajzenberg, N | 1 |
| Lacut, K | 1 |
| Couturaud, F | 1 |
| Lippert, E | 1 |
| Pan-Petesch, B | 1 |
| Ianotto, JC | 1 |
| Mora, B | 1 |
| Passamonti, F | 3 |
| Khodier, M | 1 |
| Gadó, K | 1 |
| Tefferi, A | 11 |
| Barbui, T | 16 |
| Zwicker, JI | 1 |
| Paranagama, D | 2 |
| Lessen, DS | 1 |
| Colucci, PM | 1 |
| Grunwald, MR | 1 |
| Choi, HS | 1 |
| Hong, J | 1 |
| Hwang, SM | 1 |
| Lee, JH | 1 |
| Ma, Y | 1 |
| Kim, SA | 1 |
| Lee, JY | 1 |
| Lee, JO | 1 |
| Bang, SM | 1 |
| Parasuraman, S | 1 |
| Yu, J | 1 |
| Shrestha, S | 1 |
| Wang, L | 1 |
| Baser, O | 1 |
| Scherber, R | 1 |
| Griesshammer, M | 4 |
| Kiladjian, JJ | 2 |
| Besses, C | 2 |
| Elli, EM | 1 |
| Diral, E | 1 |
| Gambacorti-Passerini, C | 1 |
| Calori, R | 1 |
| Carmosino, I | 1 |
| Breccia, M | 1 |
| Latagliata, R | 1 |
| Di Veroli, A | 1 |
| Hensley, B | 1 |
| Geyer, H | 1 |
| Mesa, R | 2 |
| Squizzato, A | 2 |
| Romualdi, E | 2 |
| Middeldorp, S | 2 |
| Panova-Noeva, M | 1 |
| Marchetti, M | 1 |
| Russo, L | 1 |
| Tartari, CJ | 1 |
| Leuzzi, A | 1 |
| Finazzi, G | 10 |
| Rambaldi, A | 2 |
| ten Cate, H | 1 |
| Falanga, A | 1 |
| Pecci, A | 1 |
| Croci, G | 1 |
| Balduini, CL | 1 |
| Boveri, E | 1 |
| Durmus, A | 1 |
| Mentese, A | 1 |
| Yilmaz, M | 1 |
| Sumer, A | 1 |
| Akalin, I | 1 |
| Topal, C | 1 |
| Alver, A | 1 |
| Michiels, JJ | 9 |
| Berneman, Z | 4 |
| Gadisseur, A | 1 |
| Lam, KH | 1 |
| De Raeve, H | 1 |
| Schroyens, W | 4 |
| Alvarez-Larrán, A | 1 |
| Yoshimoto, G | 1 |
| Miyamoto, T | 1 |
| Vannucchi, AM | 3 |
| Carobbio, A | 1 |
| Thiele, J | 2 |
| Rumi, E | 1 |
| Gisslinger, H | 4 |
| Rodeghiero, F | 2 |
| Randi, ML | 3 |
| Pieri, L | 1 |
| Pardanani, A | 1 |
| Abdel-Rahman, I | 1 |
| Murphy, C | 1 |
| Kremyanskaya, M | 2 |
| Hoffman, R | 2 |
| Aumiller, J | 1 |
| Keohane, C | 1 |
| McLornan, DP | 1 |
| Sanchez, K | 1 |
| Connor, C | 1 |
| Radia, D | 1 |
| Harrison, CN | 3 |
| Stein, BL | 1 |
| Oh, ST | 1 |
| Berenzon, D | 1 |
| Hobbs, GS | 1 |
| Rampal, RK | 1 |
| Abboud, CN | 1 |
| Adler, K | 1 |
| Heaney, ML | 1 |
| Jabbour, EJ | 1 |
| Komrokji, RS | 1 |
| Moliterno, AR | 1 |
| Ritchie, EK | 1 |
| Rice, L | 1 |
| Ahlawat, A | 1 |
| Jun-O'Connell, A | 1 |
| Salameh, J | 1 |
| Reneau, JC | 1 |
| Patnaik, MM | 1 |
| Reiter, A | 1 |
| Harrison, C | 1 |
| McMullin, MF | 2 |
| Rao, K | 1 |
| Shenoy, SB | 1 |
| Kamath, Y | 1 |
| Kapoor, S | 1 |
| Gameiro, RS | 1 |
| Rodrigues, A | 1 |
| Gonçalves, FM | 1 |
| Graça, JP | 1 |
| Santilli, F | 2 |
| Romano, M | 1 |
| Recchiuti, A | 1 |
| Dragani, A | 2 |
| Falco, A | 2 |
| Lessiani, G | 2 |
| Fioritoni, F | 2 |
| Lattanzio, S | 1 |
| Mattoscio, D | 1 |
| De Cristofaro, R | 1 |
| Rocca, B | 1 |
| Davì, G | 2 |
| Nigg, C | 1 |
| Naumann, UK | 1 |
| Käser, L | 1 |
| Struve, S | 1 |
| Beer, PA | 1 |
| Green, AR | 2 |
| Landolfi, R | 11 |
| Nicolazzi, MA | 1 |
| Porfidia, A | 1 |
| Di Gennaro, L | 5 |
| Ruggeri, M | 2 |
| Finotto, S | 1 |
| Fortuna, S | 1 |
| Robier, C | 1 |
| Neubauer, M | 1 |
| Sternad, H | 1 |
| Quehenberger, F | 1 |
| Rainer, F | 1 |
| Neumeister, P | 1 |
| Mahendradas, P | 1 |
| Shetty, R | 1 |
| Avadhani, K | 1 |
| Ross, C | 1 |
| Gupta, A | 1 |
| Shetty, BK | 1 |
| Carpenedo, M | 1 |
| Pogliani, EM | 2 |
| Prodanovic, EM | 1 |
| Frater, JL | 1 |
| Burkemper, NM | 1 |
| Hurley, MY | 1 |
| Das, S | 1 |
| Karachiwala, H | 1 |
| Cherian, SV | 1 |
| Garcha, AS | 1 |
| Jasti, S | 1 |
| Gajra, A | 1 |
| Ghazali, N | 1 |
| Collyer, JC | 1 |
| Tighe, JV | 1 |
| Finazzi, MC | 1 |
| Vatutin, NT | 1 |
| Taradin, GG | 1 |
| Bakhteeva, TD | 1 |
| Kalinkina, NV | 1 |
| Skliannaia, EV | 1 |
| Bakkour, W | 1 |
| Motta, L | 1 |
| Stewart, E | 1 |
| Lengfelder, E | 2 |
| Melear, JM | 1 |
| Goldstein, RM | 1 |
| Levy, MF | 1 |
| Molmenti, EP | 1 |
| Cooper, B | 1 |
| Netto, GJ | 1 |
| Klintmalm, GB | 1 |
| Stone, MJ | 1 |
| van Urk, H | 1 |
| Friess, D | 1 |
| Lämmle, B | 1 |
| Alberio, L | 1 |
| Spivak, J | 1 |
| Marchioli, R | 6 |
| Kutti, J | 3 |
| Tognoni, G | 4 |
| Patrono, C | 5 |
| Alliot, C | 1 |
| Dutrillaux, F | 1 |
| Maynadié, M | 1 |
| Carli, PM | 1 |
| Denes, AE | 1 |
| Elliott, MA | 2 |
| Caruso, V | 1 |
| Capnist, G | 1 |
| Chisesi, T | 1 |
| Finelli, C | 1 |
| Gugliotta, L | 2 |
| Marilus, R | 1 |
| Villegas, A | 1 |
| Rossi, D | 1 |
| Cortini, F | 1 |
| Deambrogi, C | 1 |
| Barbieri, C | 1 |
| Cerri, M | 1 |
| Franceschetti, S | 1 |
| Conconi, A | 1 |
| Capello, D | 1 |
| Gaidano, G | 1 |
| Lankipalli, R | 1 |
| Konkle, B | 1 |
| Mohler, ER | 1 |
| Novarese, L | 1 |
| Silver, RT | 2 |
| Budde, U | 1 |
| van Vliet, HH | 4 |
| De Stefano, V | 1 |
| Marfisi, R | 2 |
| Koudstaal, PJ | 1 |
| Lindemans, J | 2 |
| Neumann, HA | 1 |
| Di Nisio, M | 1 |
| Borrelli, G | 1 |
| Leone, G | 1 |
| Porreca, E | 1 |
| Rutjes, AW | 1 |
| Wahid, SF | 1 |
| Md-Anshar, F | 1 |
| Mukari, SA | 1 |
| Rahmat, R | 1 |
| Wilkins, BS | 1 |
| Erber, WN | 1 |
| Bareford, D | 1 |
| Buck, G | 1 |
| Wheatley, K | 1 |
| East, CL | 1 |
| Paul, B | 1 |
| Campbell, PJ | 1 |
| Tekin, M | 1 |
| Gökaslan, S | 1 |
| Diker, E | 1 |
| Aydoğdu, S | 1 |
| Fjellner, B | 2 |
| Ireland, H | 1 |
| Lane, DA | 1 |
| Wolff, S | 1 |
| Foadi, M | 1 |
| Schafer, AI | 1 |
| Fröhli, P | 1 |
| Graf, C | 1 |
| Rhyner, K | 1 |
| Berliner, S | 1 |
| Shoenfeld, Y | 1 |
| Shaklai, M | 1 |
| Pinkhas, J | 1 |
| Meschengieser, SS | 1 |
| Woods, AI | 1 |
| Schattner, MA | 1 |
| Lazzari, MA | 1 |
| Paris, GL | 1 |
| Waltuch, GF | 1 |
| Pagliaro, P | 1 |
| Arrigoni, L | 1 |
| Muggiasca, ML | 1 |
| Poggio, M | 1 |
| Russo, U | 1 |
| Rossi, E | 1 |
| Ongenae, K | 1 |
| Janssens, A | 1 |
| Noens, L | 1 |
| Wieme, N | 1 |
| Geerts, ML | 1 |
| Beele, H | 1 |
| Naeyaert, JM | 1 |
| van Genderen, PJ | 2 |
| Chan, AW | 1 |
| Drobac, M | 1 |
| Sternberg, L | 1 |
| Berlin, NI | 2 |
| Wasserman, LR | 3 |
| Willoughby, S | 1 |
| Pearson, TC | 2 |
| Rossi, C | 1 |
| Zerbinati, P | 1 |
| Rinaldi, V | 1 |
| Girolami, A | 1 |
| Stark, P | 1 |
| Bazzan, M | 1 |
| Brière, J | 2 |
| Green, AC | 1 |
| Fruchtmann, SM | 1 |
| Hansmann, E | 1 |
| Wehmeier, A | 1 |
| Kvasnicka, HM | 1 |
| Hasselbalch, H | 1 |
| Cervantes, F | 1 |
| Silverstein, MN | 1 |
| Turker, M | 1 |
| Ozer, EA | 1 |
| Oniz, H | 1 |
| Atabay, B | 1 |
| Yaprak, I | 1 |
| Solberg, LA | 1 |
| Hägermark, Ö | 1 |
| Ranft, K | 1 |
| Brands, W | 1 |
| Zannino, L | 1 |
| Salvadori, G | 1 |
| Myers, TJ | 1 |
| Steinberg, WM | 1 |
| Rickles, FR | 1 |
| Callis, M | 1 |
| Ciabattoni, G | 1 |
| Patrignani, P | 1 |
| Castellana, MA | 1 |
| Pogliani, E | 1 |
| Bizzi, B | 1 |
| Scheffer, MG | 1 |
| Simoons, ML | 1 |
| Roelandt, JR | 1 |
| Kurihara, A | 1 |
| Kobayashi, I | 1 |
| Tamura, K | 1 |
| Indrák, K | 1 |
| Kapustová, M | 1 |
| Hrcková, Y | 1 |
| Kubis, M | 1 |
| Scudla, V | 1 |
| Jezdinský, J | 1 |
| Kudo, I | 1 |
| Soejima, K | 1 |
| Morimoto, S | 1 |
| Sawada, Y | 1 |
| Aihara, M | 1 |
| Yoshida, Y | 1 |
| Gylling, H | 1 |
| Ikkala, E | 1 |
| Rasi, V | 1 |
| Buelli, M | 1 |
| Cortelazzo, S | 1 |
| Viero, P | 1 |
| De Gaetano, G | 1 |
| Tartaglia, AP | 1 |
| Goldberg, JD | 1 |
| Berk, PD | 1 |
| Chapman, CS | 1 |
| Swart, SS | 1 |
| Wood, JK | 1 |
| Kovaleva, LG | 1 |
| Sedova, GT | 1 |
| Krasiukova, LI | 1 |
| Abels, J | 1 |
| Steketee, J | 1 |
| Vuzevski, VD | 1 |
| Sahud, MA | 1 |
| Levin, JM | 1 |
| Ostrowski, TL | 1 |
| Gilbert, NS | 1 |
| Adams, T | 1 |
| Schutz, L | 1 |
| Goldberg, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices[NCT02252159] | 2,544 participants (Actual) | Observational | 2014-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
46 reviews available for aspirin and Polycythemia Vera
| Article | Year |
|---|---|
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera.
Topics: Animals; Aspirin; Disease Management; Female; Humans; Phlebotomy; Platelet Aggregation Inhibitors; P | 2021 |
Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review.
Topics: Aspirin; Humans; Ischemic Stroke; Janus Kinase 2; Polycythemia Vera; Thrombosis | 2022 |
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quality of | 2022 |
Treatment options and pregnancy management for patients with PV and ET.
Topics: Aspirin; Female; Humans; Hydroxyurea; Janus Kinase 2; Janus Kinase Inhibitors; Myeloproliferative Di | 2022 |
SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?
Topics: Aspirin; Humans; Hydroxyurea; Janus Kinase 2; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; | 2023 |
BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera.
Topics: Aspirin; Humans; Hydroxyurea; Mutation; Polycythemia Vera; Thrombocythemia, Essential | 2023 |
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Topics: Age Factors; Aspirin; Busulfan; Calreticulin; Disease-Free Survival; Humans; Interferon-alpha; Janus | 2020 |
Polycythemia vera: current pharmacotherapy and future directions.
Topics: Alkylating Agents; Aspirin; Hematocrit; Hematologic Agents; Hematopoiesis; Humans; Hydroxyurea; Inte | 2013 |
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Randomized Cont | 2013 |
Antiplatelet therapy in the management of myeloproliferative neoplasms.
Topics: Aspirin; Disease Management; Female; Humans; Male; Myeloproliferative Disorders; Platelet Aggregatio | 2014 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, | 2014 |
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas | 2015 |
Current and future treatment options for polycythemia vera.
Topics: Animals; Aspirin; Forecasting; Humans; Interferon-alpha; Janus Kinase 2; Phlebotomy; Polycythemia Ve | 2015 |
Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Nitr | 2015 |
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Topics: Aspirin; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Hydroxyurea; Incid | 2015 |
Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Topics: Aspirin; Diagnosis, Differential; Disease Management; Disease Progression; Humans; Janus Kinase 2; P | 2015 |
How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Topics: Antineoplastic Agents; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Nitriles; Pol | 2016 |
Investigation and Management of Erythrocytosis.
Topics: Adaptor Proteins, Signal Transducing; Aspirin; Erythropoietin; Humans; Intracellular Signaling Pepti | 2016 |
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Polycythemia V | 2008 |
Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.
Topics: Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Polycythemi | 2008 |
Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Janus Kinase 2; Leukocytosis; Mutation; Platelet Aggregation Inhibitors; Polycythem | 2010 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Idiopathic erythrocytosis: a disappearing entity.
Topics: Adult; Aspirin; Blood Viscosity; Diagnosis, Differential; Erythropoiesis; Erythropoietin; Female; He | 2009 |
Polycythemia vera.
Topics: Aspirin; Disease Progression; Fibrinolytic Agents; Humans; Janus Kinase 2; Mutation; Phlebotomy; Pol | 2010 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Front-line therapy in polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Phlebotomy; Polycythemia Vera; Risk Factors; Thrombocythemia, Essential | 2012 |
[True polycythemia: current views of pathogenesis, diagnostics and treatment].
Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hema | 2012 |
[Diagnosis and therapy of polycythemia vera in the era of JAK2].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; DNA Mutational Analysis; | 2013 |
Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
Topics: Aspirin; Bleeding Time; Hemostatics; Humans; Incidence; Platelet Activation; Platelet Aggregation; P | 2004 |
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Topics: Aged; Aspirin; Hemorrhage; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Risk Factors; Thromb | 2005 |
Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Platelet Activation; Polycythemia Vera; Thrombocythem | 2006 |
Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
Topics: Aspirin; Cooperative Behavior; Drug Therapy; Europe; Humans; Italy; Phlebotomy; Polycythemia Vera; R | 2006 |
Treatment of polycythemia vera.
Topics: Antineoplastic Agents; Aspirin; Female; Humans; Hydroxyurea; Interferons; Janus Kinase 2; Leukemia; | 2006 |
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Topics: Aspirin; Bleeding Time; Blood Platelets; Deamino Arginine Vasopressin; Hemorrhage; Humans; Microcirc | 2006 |
Massive retroperitoneal hematoma with secondary hemothorax complicating bone marrow trephine biopsy in polycythemia vera.
Topics: Aspirin; Biopsy, Needle; Bone Marrow Examination; Female; Hematoma; Hemothorax; Humans; Ilium; Middl | 2007 |
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Randomized Cont | 2008 |
Bleeding and thrombosis in the myeloproliferative disorders.
Topics: Alkylating Agents; Arachidonic Acids; Aspirin; Blood Viscosity; Epinephrine; Hematocrit; Hemorrhage; | 1984 |
Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Topics: Adult; Aged; Aspirin; Busulfan; Double-Blind Method; Erythromelalgia; Female; Gangrene; Hemorrhage; | 1996 |
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
Topics: Adult; Aged; Aspirin; Cyclooxygenase Inhibitors; Erythromelalgia; Female; Fibrinolytic Agents; Human | 1996 |
Erythromelalgia and vascular complications in polycythemia vera.
Topics: Aspirin; Erythromelalgia; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polycy | 1997 |
The use of aspirin in polycythaemia vera and primary thrombocythaemia.
Topics: Arachidonic Acid; Aspirin; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation Inhibitors; Polyc | 1998 |
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Topics: Aspirin; Bone Marrow; Bone Marrow Transplantation; Diagnosis, Differential; Follow-Up Studies; Granu | 1999 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Therapeutic options for essential thrombocythemia and polycythemia vera.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Busulfan; Fibrinolytic Agen | 2002 |
[Platelet aggregation inhibitors. Their possible use in pediatric pathology].
Topics: Age Factors; Anti-Inflammatory Agents; Aspirin; Child; Clofibrate; Dextrans; Diabetes Mellitus, Type | 1979 |
Platelet disorders: a review of disturbances in adhesion, aggregation, and release reaction.
Topics: Adenosine Diphosphate; Afibrinogenemia; Anemia; Aspirin; Blood Platelet Disorders; Connective Tissue | 1972 |
10 trials available for aspirin and Polycythemia Vera
| Article | Year |
|---|---|
Thromboembolic events in polycythemia vera.
Topics: Age Factors; Anticoagulants; Aspirin; Humans; Hydroxyurea; Interferons; Nitriles; Phlebotomy; Polycy | 2019 |
The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.
Topics: Aspirin; Biomarkers; Female; Hematologic Neoplasms; Humans; Janus Kinase 2; Male; Middle Aged; Nitri | 2015 |
Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Blood Coagulati | 2002 |
Efficacy and safety of low-dose aspirin in polycythemia vera.
Topics: Aspirin; Cardiovascular Diseases; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Hu | 2004 |
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematolo | 2008 |
Experimental and clinical pruritus. Studies on some putative peripheral mediators. The influence of ultraviolet light and transcutaneous nerve stimulation.
Topics: Animals; Aspirin; Electric Stimulation Therapy; Histamine Release; Humans; Intradermal Tests; Mast C | 1981 |
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
Topics: Adult; Aged; Aspirin; Cyclooxygenase Inhibitors; Erythromelalgia; Female; Fibrinolytic Agents; Human | 1996 |
Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Fem | 1997 |
European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
Topics: Aspirin; Dose-Response Relationship, Drug; Europe; Feasibility Studies; Female; Follow-Up Studies; H | 1997 |
Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Double-Blind Method; Female; Histam | 1979 |
78 other studies available for aspirin and Polycythemia Vera
| Article | Year |
|---|---|
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
Topics: Aged; Aspirin; Cytoreduction Surgical Procedures; Humans; Hydroxyurea; Phlebotomy; Polycythemia Vera | 2022 |
Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors-Learnings from a Large Cohort.
Topics: Aspirin; Hemorrhage; Humans; Hydroxyurea; Male; Polycythemia Vera; Risk Factors; Thrombocythemia, Es | 2022 |
[Recent advances in polycythemia vera treatment].
Topics: Aspirin; Clinical Trials as Topic; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Polycythem | 2020 |
Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Pro | 2022 |
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu | 2021 |
Cytoreductive treatment patterns among US veterans with polycythemia vera.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cytoreduction Surgical Procedures; | 2018 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Management and outcome of 11 pregnancies in women with polycythemia vera.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Disease Management; Drug Th | 2019 |
ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Female; Humans; Jan | 2013 |
Cutaneous involvement by post-polycythemia vera myelofibrosis.
Topics: Aged; Aspirin; Biopsy; Cell Lineage; Disease Progression; Drug Therapy, Combination; Fibrosis; Hemat | 2014 |
The thrombotic events in polycythemia vera patients may be related to increased oxidative stress.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Aspirin; Body Mass Index; Bone Marrow; Case-Control St | 2014 |
Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Topics: Adult; Aged; Aspirin; Cerebral Cortex; Erythromelalgia; Eye; Female; Follow-Up Studies; Humans; Isch | 2015 |
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Austria; Female; H | 2015 |
Recurrent ischaemic stroke unveils polycythaemia vera.
Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutar | 2015 |
New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.
Topics: Age Factors; Aged; Aspirin; Drug Administration Schedule; Enzyme Inhibitors; Fibrinolytic Agents; Hu | 2015 |
[Polycythemia vera: the disadvantages of overproduction].
Topics: Aged; Aspirin; Bloodletting; Diagnosis, Differential; Female; Hematocrit; Humans; Hydroxyurea; Inter | 2015 |
Pearls & Oy-sters: An isolated cranial nerve 6 palsy as a presentation of polycythemia vera.
Topics: Abducens Nerve Diseases; Aged; Aspirin; Brain; Cranial Nerves; Humans; Male; Polycythemia Vera; Troc | 2015 |
47-Year-Old Man With Pruritus.
Topics: Aspirin; Diagnosis, Differential; Disease Management; Hemoglobins; Histamine Antagonists; Humans; Ja | 2016 |
Central retinal artery occlusion as a presenting manifestation of polycythaemia vera.
Topics: Aspirin; Bone Marrow; Female; Fluorescein Angiography; Fundus Oculi; Hematocrit; Humans; Middle Aged | 2016 |
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph | 2017 |
Bumpy road to the diagnosis of polycythaemia vera.
Topics: Aged; Anticoagulants; Aspirin; Female; Humans; Phlebotomy; Polycythemia Vera; Pulmonary Embolism; Tr | 2017 |
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Aspirin; Blood; Case-Control Studies; Colony-Forming Units | 2008 |
[Thrombocytosis].
Topics: Adult; Aspirin; Biopsy, Needle; Bloodletting; Bone Marrow; Diagnosis, Differential; Female; Hematocr | 2008 |
Soluble CD40 ligand and endothelial dysfunction in aspirin-treated polycythaemia vera patients.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; CD4 | 2009 |
Treatment outcome in a cohort of young patients with polycythemia vera.
Topics: Adult; Antineoplastic Agents; Aspirin; Cohort Studies; Combined Modality Therapy; Disease Progressio | 2010 |
Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Austria; Case-Control Studies; Clopid | 2010 |
Polycythemia vera and increased hemophilic factor VIII causing acute zonal occult outer retinopathy: a case report.
Topics: Acute Disease; Aspirin; Electroretinography; Factor VIII; Fluorescein Angiography; Humans; Male; Phl | 2010 |
From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared?
Topics: Aspirin; Fibrinolytic Agents; Humans; Janus Kinase 2; Polycythemia Vera; Thrombosis | 2010 |
Pruritic indurated plaques on the legs of a 62-year-old woman--quiz case. Polycythemia vera (PCV).
Topics: Aspirin; Biopsy; Female; Humans; Hydroxyurea; Janus Kinase 2; Leg; Middle Aged; Point Mutation; Poly | 2011 |
Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report.
Topics: Aged; Anticoagulants; Aspirin; Factor Xa; Factor Xa Inhibitors; Fatal Outcome; Heparin, Low-Molecula | 2011 |
Hemimandibulectomy and vascularized fibula flap in bisphosphonate-induced mandibular osteonecrosis with polycythaemia rubra vera.
Topics: Aged, 80 and over; Alendronate; Aspirin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone De | 2013 |
A case of secondary erythromelalgia with unusual histological findings.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Erythromelalgia; Humans; Male; Middle Aged | 2013 |
Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
Topics: Aged; Aspirin; Busulfan; Erythromelalgia; Female; Fingers; Hematocrit; Humans; Male; Middle Aged; Pl | 2003 |
Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10.
Topics: Aged; Aspirin; Blood Platelet Disorders; Clopidogrel; Hemorrhage; Humans; Male; Platelet Aggregation | 2003 |
Daily aspirin--only half the answer.
Topics: Aspirin; Humans; Phlebotomy; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Thr | 2004 |
Low-dose aspirin in polycythemia vera.
Topics: Aspirin; Hematocrit; Humans; Multivariate Analysis; Patient Selection; Platelet Aggregation Inhibito | 2004 |
Low-dose aspirin in polycythemia vera.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Thrombocythemia, Es | 2004 |
Low-dose aspirin in polycythemia vera.
Topics: Aspirin; Cardiovascular Diseases; Erythrocyte Volume; Hematocrit; Humans; Platelet Aggregation Inhib | 2004 |
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.
Topics: Acute Disease; Adult; Aged; Aspirin; Databases, Factual; Disease Progression; Disease-Free Survival; | 2005 |
Platelets and thrombosis in myeloproliferative diseases.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Endothelium, Vascular; Hematocrit; Humans; Janus | 2005 |
Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Aspirin; Bone Marrow; Diagnosis, Differenti | 2007 |
An unusual case of toe ulceration.
Topics: Adult; Aspirin; Erythropoietin; Fibrinolytic Agents; Foot Ulcer; Hematocrit; Humans; Hydroxyurea; Ma | 2006 |
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.
Topics: Aged; Aspirin; Female; Follow-Up Studies; Humans; Leukocyte Count; Leukocytosis; Male; Middle Aged; | 2007 |
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thromboph
Topics: Aged; Anticoagulants; Aspirin; Drug Resistance; Erythromelalgia; Female; Humans; Ischemia; Male; Mic | 2006 |
The haematocrit and platelet target in polycythemia vera.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Female; Follow-Up Studi | 2007 |
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; | 2008 |
[Development of acute coronary syndrome in three patients with essential thrombocythemia or polycythemia vera].
Topics: Adult; Anticoagulants; Antisickling Agents; Aspirin; Coronary Angiography; Diagnosis, Differential; | 2008 |
In vivo platelet release in myeloproliferative disorders.
Topics: Aged; Aspirin; beta-Thromboglobulin; Blood Platelets; Fibrinopeptide A; Fibrinopeptide B; Humans; Mi | 1982 |
[Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid].
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Polycythemia Ver | 1983 |
Conservative treatment of Budd-Chiari syndrome in polycythemia vera.
Topics: Aspirin; Budd-Chiari Syndrome; Busulfan; Dipyridamole; Female; Furosemide; Humans; Leukapheresis; Mi | 1981 |
[Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Topics: Adult; Aspirin; Blood Platelet Disorders; Dipyridamole; Female; Humans; Leukemia, Myeloid; Male; Mid | 1981 |
Salicylate-induced bleeding problem in ophthalmic plastic surgery.
Topics: Aspirin; Bleeding Time; Blood Platelets; Eyelid Diseases; Eyelids; Female; Hemorrhage; Humans; Middl | 1982 |
Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases.
Topics: Adult; Aspirin; Female; Fibrinogen; Fibrinolytic Agents; Gestational Age; Hemoglobins; Heparin; Huma | 1996 |
Erythromelalgia: a clue to the diagnosis of polycythemia vera.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Erythromelalgia; Female; Humans; Polycythemi | 1996 |
The management of acute myocardial infarction in a patient with polycythemia rubra vera during the thrombolytic era--does it make a difference?
Topics: Adult; Anticoagulants; Aspirin; Cardiac Catheterization; Coronary Angiography; Electrocardiography; | 1997 |
Polycythemia vera: a retrospective and reprise.
Topics: Aspirin; Blood Volume; Controlled Clinical Trials as Topic; Female; Hematocrit; History, 19th Centur | 1997 |
Acute coronary disease in essential thrombocythemia and polycythemia vera.
Topics: Adult; Aged; Aging; Antisickling Agents; Aspirin; Female; Follow-Up Studies; Humans; Hydroxyurea; Ma | 1998 |
Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders.
Topics: Aspirin; Bone Marrow Examination; Clinical Trials as Topic; Clone Cells; Congresses as Topic; Diseas | 2001 |
Polycythemia vera in a 12-year-old girl: a case report.
Topics: Aspirin; Child; Drug Therapy, Combination; Female; Hemoglobins; Humans; Hydroxyurea; Leukocyte Count | 2002 |
[Complications of antithrombotic prophylaxis with acetylsalicylic acid (ASS) in polycythemia (author's transl)].
Topics: Aged; Aspirin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Male; Polycythemia Vera; Thromb | 1978 |
Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin.
Topics: Aspirin; Drug Resistance; Humans; Intestine, Small; Male; Mesenteric Vascular Occlusion; Middle Aged | 1979 |
[Ischemic lesions in polycythaemia vera (author's transl)].
Topics: Aspirin; Dipyridamole; Female; Foot; Humans; Ischemia; Male; Middle Aged; Pain; Polycythemia Vera; S | 1977 |
Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.
Topics: Adult; Aged; Aspirin; Blood Platelets; Female; Humans; Kinetics; Leukotriene E4; Male; Middle Aged; | 1992 |
Thrombocythemia and coronary artery disease.
Topics: Adult; Aged; Aspirin; Busulfan; Coronary Disease; Female; Humans; Male; Middle Aged; Polycythemia Ve | 1991 |
[Clinical evaluation of the control of antiplatelet therapy through platelet aggregation rate on polycythemia vera associated with thrombocytosis and erythromelalgia].
Topics: Aspirin; Drug Evaluation; Erythromelalgia; Female; Fingers; Humans; Indomethacin; Middle Aged; Plate | 1989 |
Comparison of the effects of acylpyrin, curantyl and ticlid on some platelet functions in patients with polycythemia vera.
Topics: Adult; Aged; Aspirin; Blood Platelets; Dipyridamole; Female; Humans; Male; Middle Aged; Platelet Agg | 1985 |
[Polycythemia vera associated with erythromelalgia].
Topics: Adult; Aspirin; Erythromelalgia; Humans; Male; Polycythemia Vera | 1988 |
[Erythromelalgia].
Topics: Aged; Aspirin; Erythromelalgia; Female; Humans; Male; Middle Aged; Polycythemia Vera; Thrombocytosis | 1987 |
Aspirin and risk of bleeding in patients with thrombocythemia.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Adolescent; Adult; Aged; Aspirin; Bleeding Time; Blood P | 1987 |
Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.
Topics: Aspirin; Dipyridamole; Female; Hemorrhage; Humans; Male; Phosphorus Radioisotopes; Platelet Aggregat | 1986 |
Oesophageal apoplexy associated with aspirin ingestion in polycythaemia rubra vera.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Esophagus; Female; Hemorrhage; Humans; Polycythemia Vera | 1986 |
A cooperative study of polycythemia vera.
Topics: Aspirin; Chlorambucil; Dipyridamole; Humans; Leukemia; Polycythemia Vera; Prognosis | 1985 |
[Preventive correction of hemostasis in patients with polycythemia vera].
Topics: Aspirin; Humans; Niacin; Pentoxifylline; Polycythemia Vera; Theobromine; Thrombosis | 1986 |
Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia.
Topics: Adult; Aged; Analgesics; Arteries; Arterioles; Arteritis; Aspirin; Blood Platelets; Erythromelalgia; | 1985 |
Thrombotic-hemorrhagic diathesis of polycythemia vera treated with aspirin.
Topics: Aspirin; Blood Cell Count; Blood Platelets; Bloodletting; Disseminated Intravascular Coagulation; Fe | 1974 |
Letter: Aspirin treatment in polycythemia.
Topics: Adult; Aspirin; Humans; Male; Polycythemia Vera | 1974 |
Platelet function abnormalities in the myeloproliferative disorders.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Cell Count; Blood Platelets; Collagen; Epinephrin | 1974 |
Polycythemia vera complicated by acute leukemia and a rapidly enlarging mass in the left upper abdominal quadrant.
Topics: Aspirin; Female; Heart Arrest; Humans; Leukemia, Myeloid; Metaraminol; Middle Aged; Polycythemia Ver | 1967 |